Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New funding for research into enzootic pneumonia
The bacteria responsible for the disease is present in 80 per cent of UK herds.
Government awards funding to researchers developing vaccine.

Researchers at the Royal Veterinary College have been awarded funding to create a vaccine for enzootic pneumonia by the Department for Environment, Food and Rural Affairs and the Biotechnology and Biological Sciences Research Council (BBSRC).

Enzootic pneumonia is the most common respiratory disease in pigs, with Mycoplasma hyopneumoniae (M.hyop), the bacteria which causes the disease, present in 80 per cent of UK herds. It is predominantly transmitted to piglets through lactation from an infected pig and can result in a 16 per cent reduction in growth.

Currently, treatment relies on antibiotics, with M.hyop susceptible to several varieties. However, owing to the need to reduce the overall use of antibiotics in veterinary medicine to prevent drug-resistant strains of bacteria developing, scientists are keen to find an alternative.

The research team, which will include Professor Dirk Werling, Dr Rob Noad, and Dr Sonja Jeckel, will work on developing the first commercially available vaccine for enzootic pneumonia. The researchers will also study how to improve protocols to eliminate M.hyop from pig herds to further minimise the potential transmission of the disease.

Previous research, funded by the BBSRC and the Agriculture and Horticulture Development Board, identified the genes which allow the pathogen to survive in pigs.

Professor Werling said: “Infection of Mycoplasma hyopneumoniae is a really debilitating disease in pigs that causes huge economic losses for farmers. I am very pleased that we will be able to continue working with a pharmaceutical partner to develop a new vaccine using state-of the-art technologies.”


Image (C) Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.